person · Reporting owner

COX CARRIE SMITH

Disclosed activity across 9 companies

Tapewire entity: 10815
SEC CIK: 0001110753

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CARDINAL HEALTH INCCAH · Entity 3014	Director	November 09, 2022	November 10, 2022
Cartesian Therapeutics, Inc.RNAC · Entity 6015	Director	January 02, 2025	January 06, 2025
Organon & Co.OGN · Entity 4115	Director · Executive Chair	November 12, 2025	November 13, 2025
Solventum CorpSOLV · Entity 1645	Director	May 15, 2026	May 18, 2026
TEXAS INSTRUMENTS INCTXN · Entity 2834	Director	May 13, 2026	May 14, 2026
electroCore, Inc.ECOR · Entity 6900	Director	June 07, 2019	June 12, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CARDINAL HEALTH INC

Report date November 09, 2022 · Filed November 10, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	41,631	Reported balance After 2022-11-09 transaction · row 1 1 source row Row 1 · 2022-11-09 · Grant · Acquired 2,308 · Balance 41,631 F1: Grant of restricted share units that will vest on November 9, 2023, except if the 2023 Annual Meeting of Shareholders is prior to November 9, 2023, then the restricted share units will vest on the date of the 2023 Annual Meeting of Shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: Grant of restricted share units that will vest on November 9, 2023, except if the 2023 Annual Meeting of Shareholders is prior to November 9, 2023, then the restricted share units will vest on the date of the 2023 Annual Meeting of Shareholders.

Cartesian Therapeutics, Inc.

Report date January 02, 2025 · Filed January 06, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	15,629	Reported balance After 2025-01-02 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-01-02 · Grant · Acquired 2,600 · Balance 15,629 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026. F2: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.93 · Expires 2035-01-01	Direct	8,000	Reported balance After 2025-01-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-01-02 · Grant · Acquired 8,000 · Balance 8,000
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.66 · Expires 2034-01-01	Direct	8,266	Reported balance Holding disclosure · report date 2025-01-02 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 8,266 F3: This award vests in 36 equal monthly installments following the date of grant, so that it shall be fully vested on January 2, 2027. F2: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026.

F2: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F3: This award vests in 36 equal monthly installments following the date of grant, so that it shall be fully vested on January 2, 2027.

Organon & Co.

Report date November 12, 2025 · Filed November 13, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectIRA	77,869	Reported balance After 2025-11-12 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-11-12 · Purchase · Acquired 65,400 · Balance 77,869 F1: The price reported is a weighted average price of $7.6721. These shares were purchased in multiple transactions at prices ranging from $7.6630 to $7.6899, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price of $7.6721. These shares were purchased in multiple transactions at prices ranging from $7.6630 to $7.6899, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Solventum Corp

Report date May 15, 2026 · Filed May 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	4,848	Reported balance After 2026-05-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-15 · Grant · Acquired 4,848 · Balance 4,848 F1: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.

F2: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.

TEXAS INSTRUMENTS INC

Report date May 13, 2026 · Filed May 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	37,626	Ending reported balance After 2026-05-13 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2026-05-13 · Exercise / conversion · Acquired 4,306 · Balance 41,932 Row 2 · 2026-05-13 · Exercise / conversion · Acquired 4,532 · Balance 46,464 Row 3 · 2026-05-13 · Sale · Disposed 8,393 · Balance 38,071 F1: The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $305.91 to $306.89. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. Row 4 · 2026-05-13 · Sale · Disposed 445 · Balance 37,626 F2: The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $306.94 to $307.24. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price.
NQ Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $110.15 · Expires 2028-01-25	Direct	0	Reported balance After 2026-05-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-13 · Exercise / conversion · Disposed 4,306 · Balance 0 F3: The option became exercisable in four equal annual installments beginning on January 25, 2019.
NQ Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.41 · Expires 2029-01-25	Direct	0	Reported balance After 2026-05-13 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-05-13 · Exercise / conversion · Disposed 4,532 · Balance 0 F4: The option became exercisable in four equal annual installments beginning on January 25, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $305.91 to $306.89. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price.

F2: The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $306.94 to $307.24. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price.

F3: The option became exercisable in four equal annual installments beginning on January 25, 2019.

F4: The option became exercisable in four equal annual installments beginning on January 25, 2020.

electroCore, Inc.

Report date June 07, 2019 · Filed June 12, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-06-08	Direct	66,964	Reported balance After 2019-06-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-07 · Grant · Acquired 66,964 · Balance 66,964 F1: The Deferred Stock Units vest upon the close of business on the day before the next annual meeting of stockholders following the date hereof.

Filing footnotes · ownership attribution and instrument terms

F1: The Deferred Stock Units vest upon the close of business on the day before the next annual meeting of stockholders following the date hereof.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARRAY BIOPHARMA INC

Report date July 30, 2019 · Filed July 30, 2019

Section 16 reporting ended · disclosed 2019-07-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2019-07-30 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-07-30 · Disposition to issuer · Disposed 8,000 · Balance 10,000 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Row 2 · 2019-07-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.93 · Expires 2028-08-09	Direct	Reported balance After 2019-07-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-07-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F4: The option provided for vesting in four equal annual installments beginning on August 9, 2019.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.55 · Expires 2028-10-25	Direct	Reported balance After 2019-07-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-07-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F4: The option provided for vesting in four equal annual installments beginning on August 9, 2019. F6: The option provided for vesting in four equal annual installments beginning on October 25, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.

F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.

F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.

F4: The option provided for vesting in four equal annual installments beginning on August 9, 2019.

F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.

F6: The option provided for vesting in four equal annual installments beginning on October 25, 2019.

CELGENE CORP /DE/

Report date November 20, 2019 · Filed November 22, 2019

Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-11-20 transaction · row 1 1 source row Row 1 · 2019-11-20 · Disposition to issuer · Disposed 39,535 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.00 · Expires 2021-06-15	Direct	Reported balance After 2019-11-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-20 · Disposition to issuer · Disposed 18,600 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.80 · Expires 2022-06-13	Direct	Reported balance After 2019-11-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-20 · Disposition to issuer · Disposed 18,600 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.06 · Expires 2023-06-12	Direct	Reported balance After 2019-11-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-11-20 · Disposition to issuer · Disposed 18,600 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.50 · Expires 2024-07-01	Direct	Reported balance After 2019-11-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-11-20 · Disposition to issuer · Disposed 20,700 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.16 · Expires 2025-06-17	Direct	Reported balance After 2019-11-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.98 · Expires 2026-06-15	Direct	Reported balance After 2019-11-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-11-20 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.04 · Expires 2027-06-14	Direct	Reported balance After 2019-11-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-11-20 · Disposition to issuer · Disposed 10,500 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.38 · Expires 2028-06-13	Direct	Reported balance After 2019-11-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-11-20 · Disposition to issuer · Disposed 13,266 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-11-20 · Disposition to issuer · Disposed 900 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2019-11-20 · Disposition to issuer · Disposed 1,454 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2019-11-20 · Disposition to issuer · Disposed 4,756 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2019-11-20 · Disposition to issuer · Disposed 6,200 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2019-11-20 · Disposition to issuer · Disposed 1,000 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2019-11-20 · Disposition to issuer · Disposed 1,125 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.

F2: This option was fully exercisable.

F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.

F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.

Merck & Co., Inc.

Report date November 03, 2009 · Filed November 04, 2009

Section 16 reporting ended · disclosed 2009-11-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2009-11-03 transaction · row 1 1 source row Row 1 · 2009-11-03 · Disposition to issuer · Disposed 169,534 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.23 · Expires 2013-05-18	Direct	Reported balance After 2009-11-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2009-11-03 · Disposition to issuer · Disposed 375,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.57 · Expires 2014-04-30	Direct	Reported balance After 2009-11-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2009-11-03 · Disposition to issuer · Disposed 400,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.70 · Expires 2015-04-24	Direct	Reported balance After 2009-11-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2009-11-03 · Disposition to issuer · Disposed 400,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2015-04-30	Direct	Reported balance After 2009-11-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2009-11-03 · Disposition to issuer · Disposed 270,000 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.91 · Expires 2016-04-30	Direct	Reported balance After 2009-11-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2009-11-03 · Disposition to issuer · Disposed 264,600 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
Phantom Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2009-11-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2009-11-03 · Disposition to issuer · Disposed 66,552.22 · Balance 0 F4: Each unit of phantom stock is the economic equivalent of one share of common stock. F5: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash.

F2: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.

F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F4: Each unit of phantom stock is the economic equivalent of one share of common stock.

F5: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 15, 2026 Filed May 18, 2026 17:39 UTC	Solventum Corp SOLV · Entity 1645	GrantRestricted Stock Units · Derivative	4,848	$0.00	$0.00	Disclosure SEC source: 0001110753-26-000006 · wk-form4_1779140353.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,848 Underlying: Common Stock · 4,848 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date. F2 · derivative.expiration_date: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date. Read SEC document
May 13, 2026 Filed May 14, 2026 22:49 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	Exercise / conversionNQ Stock Option (Right to Buy) · Derivative	4,532	$0.00 Strike: $104.41	$0.00	Disclosure SEC source: 0000097476-26-000137 · wk-form4_1778798964.xml · derivative · entry 6 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,532 shares Expires 2029-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in four equal annual installments beginning on January 25, 2020. Read SEC document
May 13, 2026 Filed May 14, 2026 22:49 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	Exercise / conversionNQ Stock Option (Right to Buy) · Derivative	4,306	$0.00 Strike: $110.15	$0.00	Disclosure SEC source: 0000097476-26-000137 · wk-form4_1778798964.xml · derivative · entry 5 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,306 shares Expires 2028-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option became exercisable in four equal annual installments beginning on January 25, 2019. Read SEC document
May 13, 2026 Filed May 14, 2026 22:49 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	SaleCommon Stock	445	$307.04	$136,634.27	Disclosure SEC source: 0000097476-26-000137 · wk-form4_1778798964.xml · nonDerivative · entry 4 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,626 F2 · price: The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $306.94 to $307.24. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. Read SEC document
May 13, 2026 Filed May 14, 2026 22:49 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	SaleCommon Stock	8,393	$306.37	$2,571,394.46	Disclosure SEC source: 0000097476-26-000137 · wk-form4_1778798964.xml · nonDerivative · entry 3 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,071 F1 · price: The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $305.91 to $306.89. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. Read SEC document
May 13, 2026 Filed May 14, 2026 22:49 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	Exercise / conversionCommon Stock	4,532	$104.41	$473,186.12	Disclosure SEC source: 0000097476-26-000137 · wk-form4_1778798964.xml · nonDerivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 13, 2026 Filed May 14, 2026 22:49 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	Exercise / conversionCommon Stock	4,306	$110.15	$474,305.90	Disclosure SEC source: 0000097476-26-000137 · wk-form4_1778798964.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 30, 2026 Filed May 1, 2026 20:26 UTC	Solventum Corp SOLV · Entity 1645	Exercise / conversionRestricted Stock Units · Derivative	4,916	$0.00	$0.00	Disclosure SEC source: 0001110753-26-000004 · wk-form4_1777667174.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,916 shares Expires 2035-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The RSUs are fully vested. Read SEC document
April 30, 2026 Filed May 1, 2026 20:26 UTC	Solventum Corp SOLV · Entity 1645	Exercise / conversionCommon Stock	4,916	$0.00	$0.00	Disclosure SEC source: 0001110753-26-000004 · wk-form4_1777667174.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 27, 2026 Filed Mar 30, 2026 23:44 UTC	Solventum Corp SOLV · Entity 1645	Exercise / conversionRestricted Stock Units · Derivative	6,336	$0.00	$0.00	Disclosure SEC source: 0001110753-26-000002 · wk-form4_1774914270.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,336 shares Expires 2034-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The RSUs are fully vested. Read SEC document
March 27, 2026 Filed Mar 30, 2026 23:44 UTC	Solventum Corp SOLV · Entity 1645	Exercise / conversionCommon Stock	6,336	$0.00	$0.00	Disclosure SEC source: 0001110753-26-000002 · wk-form4_1774914270.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 29, 2026 Filed Feb 2, 2026 21:24 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	GrantNQ Stock Option (Right to Buy) · Derivative	1,860	$0.00 Strike: $218.97	$0.00	Disclosure SEC source: 0000097476-26-000044 · wk-form4_1770067446.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,860 Underlying: Common Stock · 1,860 shares Expires 2036-01-29 F2 · derivative.exercise_date: The stock option becomes exercisable in four equal installments beginning on January 29, 2027. Read SEC document
January 29, 2026 Filed Feb 2, 2026 21:24 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	GrantCommon Stock	525	$0.00	$0.00	Disclosure SEC source: 0000097476-26-000044 · wk-form4_1770067446.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,626 F1 · shares: Award of restricted stock units granted under the Texas Instruments 2018 Director Compensation Plan. Read SEC document
November 12, 2025 Filed Nov 13, 2025 21:05 UTC	Organon & Co. OGN · Entity 4115	PurchaseCommon Stock	65,400	$7.67	$501,755.34	Disclosure SEC source: 0001628280-25-052004 · wk-form4_1763067905.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director · Executive Chair 10b5-1 filing: No plan indicated Ownership: Indirect · IRA Disclosed balance after: 77,869 F1 · price: The price reported is a weighted average price of $7.6721. These shares were purchased in multiple transactions at prices ranging from $7.6630 to $7.6899, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
June 13, 2025 Filed Jun 16, 2025 21:17 UTC	Organon & Co. OGN · Entity 4115	GrantPhantom Stock · Derivative	23,904.382	$10.04	$240,000.00	Disclosure SEC source: 0001821825-25-000041 · wk-form4_1750108628.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,029.769 Underlying: Common Stock · 23,904.382 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025. Read SEC document
May 14, 2025 Filed May 15, 2025 20:09 UTC	Organon & Co. OGN · Entity 4115	PurchaseCommon Stock	12,469	$8.07	$100,591.16	Disclosure SEC source: 0001821825-25-000037 · wk-form4_1747339741.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,469 F1 · price: The price reported is a weighted average price (which was $8.06727998, rounded due to character limitations in the price field). These shares were purchased in multiple transactions at prices ranging from $8.059 to $8.07, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
May 13, 2025 Filed May 15, 2025 20:23 UTC	Solventum Corp SOLV · Entity 1645	Exercise / conversionRestricted Stock Units · Derivative	5,148	$0.00	$0.00	Disclosure SEC source: 0001628280-25-025969 · wk-form4_1747340612.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,148 shares Expires 2034-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement. F2 · derivative.exercise_date: The RSUs fully vested on May 13, 2025. Read SEC document
May 13, 2025 Filed May 15, 2025 20:23 UTC	Solventum Corp SOLV · Entity 1645	Exercise / conversionCommon Stock	5,148	$0.00	$0.00	Disclosure SEC source: 0001628280-25-025969 · wk-form4_1747340612.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 30, 2025 Filed May 2, 2025 20:34 UTC	Solventum Corp SOLV · Entity 1645	GrantRestricted Stock Units · Derivative	4,916	$0.00	$0.00	Disclosure SEC source: 0001628280-25-021885 · wk-form4_1746218073.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,916 Underlying: Common Stock · 4,916 shares Expires 2035-04-30 F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement. F2 · derivative.exercise_date: The RSUs shall fully vest on April 30, 2026, subject to continued service through the vesting date. Read SEC document
January 27, 2025 Filed Jan 29, 2025 21:43 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	GrantNQ Stock Option (Right to Buy) · Derivative	2,551	$0.00 Strike: $187.03	$0.00	Disclosure SEC source: 0001127602-25-002263 · form4.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,551 Underlying: Common Stock · 2,551 shares Expires 2035-01-27 F2 · derivative.exercise_date: The stock option becomes exercisable in four equal installments beginning on January 27, 2026. Read SEC document
January 27, 2025 Filed Jan 29, 2025 21:43 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	GrantCommon Stock	614	$0.00	$0.00	Disclosure SEC source: 0001127602-25-002263 · form4.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,101 F1 · shares: Award of restricted stock units granted under the Texas Instruments 2018 Director Compensation Plan. Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:19 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantStock Option (Right to Buy) · Derivative	8,000	$0.00 Strike: $16.93	$0.00	Disclosure SEC source: 0001453687-25-000016 · wk-form4_1736198350.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2035-01-01 Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:19 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantCommon Stock	2,600	$0.00	$0.00	Disclosure SEC source: 0001453687-25-000016 · wk-form4_1736198350.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,629 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026. F2 · balance_after: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document
June 07, 2024 Filed Jun 11, 2024 19:17 UTC	Organon & Co. OGN · Entity 4115	GrantPhantom Stock · Derivative	9,638.554	$20.75	$200,000.00	Disclosure SEC source: 0001821825-24-000076 · wk-form4_1718133431.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,059.859 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document
May 13, 2024 Filed May 15, 2024 20:52 UTC	Solventum Corp SOLV · Entity 1645	GrantRestricted Stock Units · Derivative	6,336	$0.00	$0.00	Disclosure SEC source: 0001127602-24-015491 · form4.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,484 Underlying: Common Stock · 6,336 shares Expires 2034-05-13 F1 · derivative.exercise_price: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs shall fully vest on March 27, 2026, subject to continued service through the vesting date. Read SEC document
May 13, 2024 Filed May 15, 2024 20:52 UTC	Solventum Corp SOLV · Entity 1645	GrantRestricted Stock Units · Derivative	5,148	$0.00	$0.00	Disclosure SEC source: 0001127602-24-015491 · form4.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,148 Underlying: Common Stock · 5,148 shares Expires 2034-05-13 F1 · derivative.exercise_price: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement. F2 · derivative.exercise_date: The RSUs shall fully vest on May 13, 2025, subject to continued service through the vesting date. Read SEC document
January 25, 2024 Filed Jan 29, 2024 21:37 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	GrantNQ Stock Option (Right to Buy) · Derivative	3,066	$0.00 Strike: $167.42	$0.00	Disclosure SEC source: 0001127602-24-002436 · form4.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,066 Underlying: Common Stock · 3,066 shares Expires 2034-01-25 F2 · derivative.exercise_date: The stock option becomes exercisable in four equal annual installments beginning on January 25, 2025. Read SEC document
January 25, 2024 Filed Jan 29, 2024 21:37 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	GrantCommon Stock	686	$0.00	$0.00	Disclosure SEC source: 0001127602-24-002436 · form4.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,487 F1 · shares: Award of restricted stock units granted under the Texas Instruments 2018 Director Compensation Plan. Read SEC document
January 02, 2024 Filed Jan 4, 2024 22:05 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantStock Option (Right to Buy) · Derivative	248,000	$0.00 Strike: $0.66	$0.00	Disclosure SEC source: 0001453687-24-000019 · wk-form4_1704405888.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,000 Underlying: Common Stock · 248,000 shares Expires 2034-01-01 F2 · derivative.exercise_date: This award will vest in 36 equal monthly installments, so that it shall be fully vested on January 2, 2027. Read SEC document
January 02, 2024 Filed Jan 4, 2024 22:05 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantCommon Stock	178,000	$0.00	$0.00	Disclosure SEC source: 0001453687-24-000019 · wk-form4_1704405888.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,881 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments so that the underlying shares will be fully vested on January 2, 2027. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:14 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	107,500	$0.93 Strike: $1.13	$99,975.00	Disclosure SEC source: 0001453687-23-000081 · wk-form4_1700086481.xml · derivative · entry 5 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,500 shares Expires 2033-01-01 F5 · derivative.exercise_date: This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $99,975, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:14 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	60,000	Not disclosed Strike: $3.31	Not disclosed	Disclosure SEC source: 0001453687-23-000081 · wk-form4_1700086481.xml · derivative · entry 4 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2032-01-02 F4 · price: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. F4 · derivative.exercise_date: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:14 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	60,000	Not disclosed Strike: $4.01	Not disclosed	Disclosure SEC source: 0001453687-23-000081 · wk-form4_1700086481.xml · derivative · entry 3 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2031-03-29 F3 · price: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. F3 · derivative.exercise_date: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:14 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	30,000	Not disclosed Strike: $3.00	Not disclosed	Disclosure SEC source: 0001453687-23-000081 · wk-form4_1700086481.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2030-06-18 F2 · price: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. F2 · derivative.exercise_date: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:14 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	20,000	$0.74 Strike: $1.32	$14,800.00	Disclosure SEC source: 0001453687-23-000081 · wk-form4_1700086481.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-11-19 F1 · derivative.exercise_date: This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on November 20, 2019, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. in exchange for a cash payment of $14,800, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. Read SEC document
July 31, 2023 Filed Aug 3, 2023 17:06 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	Exercise / conversionNQ Stock Option (Right to Buy) · Derivative	6,065	$0.00 Strike: $79.26	$0.00	Disclosure SEC source: 0001127602-23-021922 · form4.xml · derivative · entry 5 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,065 shares Expires 2027-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became exercisable in four equal annual installments beginning on January 26, 2018. Read SEC document
July 31, 2023 Filed Aug 3, 2023 17:06 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	Exercise / conversionNQ Stock Option (Right to Buy) · Derivative	9,990	$0.00 Strike: $52.93	$0.00	Disclosure SEC source: 0001127602-23-021922 · form4.xml · derivative · entry 4 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,990 shares Expires 2026-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option became exercisable in four equal annual installments beginning on January 29, 2017. Read SEC document
July 31, 2023 Filed Aug 3, 2023 17:06 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	SaleCommon Stock	16,055	$180.04	$2,890,542.20	Disclosure SEC source: 0001127602-23-021922 · form4.xml · nonDerivative · entry 3 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,801 Read SEC document
July 31, 2023 Filed Aug 3, 2023 17:06 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	Exercise / conversionCommon Stock	6,065	$79.26	$480,711.90	Disclosure SEC source: 0001127602-23-021922 · form4.xml · nonDerivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 31, 2023 Filed Aug 3, 2023 17:06 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	Exercise / conversionCommon Stock	9,990	$52.93	$528,770.70	Disclosure SEC source: 0001127602-23-021922 · form4.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 09, 2023 Filed Jun 13, 2023 20:46 UTC	Organon & Co. OGN · Entity 4115	GrantPhantom Stock · Derivative	10,086	$19.83	$200,005.38	Disclosure SEC source: 0001209191-23-036752 · doc4.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,232 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document
January 26, 2023 Filed Jan 30, 2023 21:55 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	GrantNQ Stock Option (Right to Buy) · Derivative	2,159	$0.00 Strike: $174.10	$0.00	Disclosure SEC source: 0001127602-23-002679 · form4.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,159 Underlying: Common Stock · 2,159 shares Expires 2033-01-26 F2 · derivative.exercise_date: The option becomes exercisable in four equal annual installments beginning on January 26, 2024. Read SEC document
January 26, 2023 Filed Jan 30, 2023 21:55 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	GrantCommon Stock	574	$0.00	$0.00	Disclosure SEC source: 0001127602-23-002679 · form4.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,801 F1 · shares: Award of restricted stock units granted under the Texas Instruments 2018 Director Compensation Plan. Read SEC document
January 02, 2023 Filed Jan 4, 2023 22:03 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantStock Option (Right to Buy) · Derivative	107,500	$0.00 Strike: $1.13	$0.00	Disclosure SEC source: 0001453687-23-000021 · wf-form4_167286975633037.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,500 Underlying: Common Stock · 107,500 shares Expires 2033-01-01 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 2, 2024. Read SEC document
November 09, 2022 Filed Nov 10, 2022 21:25 UTC	CARDINAL HEALTH INC CAH · Entity 3014	GrantCommon Shares	2,308	$0.00	$0.00	Disclosure SEC source: 0000721371-22-000156 · wf-form4_166811550524579.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,631 F1 · shares: Grant of restricted share units that will vest on November 9, 2023, except if the 2023 Annual Meeting of Shareholders is prior to November 9, 2023, then the restricted share units will vest on the date of the 2023 Annual Meeting of Shareholders. Read SEC document
June 13, 2022 Filed Jun 15, 2022 20:16 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	130,000	$1.15	$149,799.00	Disclosure SEC source: 0001453687-22-000104 · wf-form4_165532415494758.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,881 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $1.13 to $1.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
June 10, 2022 Filed Jun 14, 2022 23:31 UTC	Organon & Co. OGN · Entity 4115	GrantPhantom Stock · Derivative	5,640	$35.46	$199,994.40	Disclosure SEC source: 0001104659-22-071133 · tm2218336-1_4seq1.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,187 Underlying: Common Stock · 5,640 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 13, 2021, December 16, 2021 and March 17, 2022. Read SEC document
January 27, 2022 Filed Jan 31, 2022 22:29 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	GrantNQ Stock Option (Right to Buy) · Derivative	2,512	$0.00 Strike: $174.81	$0.00	Disclosure SEC source: 0001127602-22-002570 · form4.xml · derivative · entry 2 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,512 Underlying: Common Stock · 2,512 shares Expires 2032-01-27 F2 · derivative.exercise_date: The option becomes exercisable in four equal annual installments beginning on January 27, 2023. Read SEC document
January 27, 2022 Filed Jan 31, 2022 22:29 UTC	TEXAS INSTRUMENTS INC TXN · Entity 2834	GrantCommon Stock	572	$0.00	$0.00	Disclosure SEC source: 0001127602-22-002570 · form4.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,227 F1 · shares: Award of restricted stock units granted under the Texas Instruments 2018 Director Compensation Plan. Read SEC document
January 03, 2022 Filed Jan 5, 2022 21:32 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantStock Option (Right to Buy) · Derivative	60,000	$0.00 Strike: $3.31	$0.00	Disclosure SEC source: 0001453687-22-000017 · wf-form4_164141832752094.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 3, 2023. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.